PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2220 Views
-
Last post by NHE
-
- 0 Replies
- 1078 Views
-
Last post by NHE
-
- 0 Replies
- 11120 Views
-
Last post by NHE
-
- 0 Replies
- 2122 Views
-
Last post by Firidion
-
- 1 Replies
- 1365 Views
-
Last post by vesta
-
- 0 Replies
- 2113 Views
-
Last post by frodo
-
- 0 Replies
- 2029 Views
-
Last post by NHE
-
- 0 Replies
- 1531 Views
-
Last post by NHE
-
- 4 Replies
- 2548 Views
-
Last post by JohnC777